Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.

Authors

Douglas W. Blayney

Stanford University, Stanford, CA

Douglas W. Blayney , Yuankai Shi , Igor Bondarenko , Stephan Ogenstad , Qingyuan Zhang , Lihua Du , Lan Huang , Ramon Mohanlal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Head-to-head comparison of the non-G-CSF small molecule single agent (SA) plinabulin with SA pegfilgrastim for the prevention of docetaxel chemotherapy (chemo)-induced neutropenia (CIN) in the protective-1 trial.

First Author: Douglas W. Blayney

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.

First Author: Douglas W. Blayney

insert_chart_outlined

Poster

2019 Supportive Care in Oncology Symposium

bookmark_border

Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.

First Author: Lee S. Schwartzberg

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).

First Author: Douglas W. Blayney